Does melatonin play a role in aging processes?

Journal of Physiology and Pharmacology

Volumn 58, Issue SUPPL. 6, 2007, Pages 105-113

  Karasek, M ^a,b  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

Author keywords

Aging; Immune system; Neurodegenerative diseases; Quality of life

Indexed keywords

MELATONIN;

AGING; CIRCADIAN RHYTHM; DIET SUPPLEMENTATION; DRUG EFFECT; HORMONE SYNTHESIS; HUMAN; PINEAL BODY; POLAND; QUALITY OF LIFE; REVIEW;

AGED; AGING; ANTIOXIDANTS; CIRCADIAN RHYTHM; FREE RADICALS; HUMANS; IMMUNE SYSTEM; MELATONIN; PINEAL GLAND; QUALITY OF LIFE; SLEEP DISORDERS;

EID: 38149026387     PISSN: 08675910     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Lerner AB, Case JD, Takahashi Y, Lee TH, Mori N. Isolation of melatonin, pineal factor that lightens melanocytes. J Am Chem Soc 1958; 80: 2587.
2. Lerner AB, Case JD, Heinzelman RU. Structure of melatonin. J Am Chem Soc 1959; 81: 6084-6085.
3. Troen BR. The biology of ageing. Mount Sinai J Med 2003; 70: 3-22.
4. United Nations, Department of Economic and Social Affairs. World Population Ageing: 1950-2050. New York: United Nations, 2001.
5. Karasek M. Melatonin, human aging, and age-related diseases. Exp Gerontol 2004; 39: 1723-1729.
6. Karasek M. Role of melatonin in aging. In Aging and Age-Related Diseases: the Basics, M Karasek (ed). Hauppage, NY, Nova Science, 2006, pp. 83-102.
7. Pandi-Perumal SR, Srinivassan V, Maestroni GJM, Cardinali DP, Poeggeler B, Harderland R. Melatonin. Nature's most versatile biological signal? FEBS J 2006; 273: 2813-2836.
8. Harderland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res 2003; 34: 233-241.
9. Arendt J. Melatonin and the mammalian pineal gland. London, Chapman & Hall, 1995.
10. Reiter RJ. Melatonin: clinical relevance. Best Pract Res Clin Endocrinol Metab 2003; 17: 273-285.
11. Sugden D. Adrenergic mechanisms regulating pineal melatonin synthesis. Adv Pineal Res 1991; 5: 33-38.
12. Kennaway DJ, Stamp GE, Goble FC. Development of melatonin production in infants and the impact of prematurity. J Clin Endocrinol Metab 1992; 75: 367-369.
13. Bergiannaki JD, Soldatos CR, Paparrigopoulos TJ, Syrengelas M, Stefanis CN. Low and high melatonin excretors among healthy individuals. J Pineal Res 1995; 18: 159-164.
14. Selmaoui B, Touitou Y. Reproducibility of the circadian rhythm of serum cortisol and melatonin in healthy subjects: a study of three different cycles over six weeks. Life Sci 2003; 73: 3339-3349.
15. Harman, D. Ageing: a theory based on free radical and radiation chemistry. J Gerontol 1956; 11: 298-300.
16. Harman D. Free radical theory of aging. Mutat Res 1992; 275: 257-266.
17. Harman D. Aging: phenomena and theories. Ann N Y Acad Sci 1998, 854, 1-7.
18. Tan DX, Chen LD, Poeggeler B, Manchester LC, Reiter RJ. Melatonin: a potent, endogenous, hydroxyl radical scavenger. Endocrine J 1993; 1: 57-60.
19. Reiter RJ. Oxygen radical detoxification processes during aging: The functional importance of melatonin. Aging Clin Exp Res 1995; 7: 430-351.
20. Reiter RJ. Oxidative damage in the central nervous system: protection by melatonin. Progr Neurobiol 1998; 56: 359-384.
21. Reiter RJ, Tan DX, Allegra M. Melatonin: reducing molecular pathology and dysfunction due to free radicals and associated reactants. Neuro Endocrinol Lett 2002; 23(suppl 1): 3-8.
22. Benot S, Goberna R, Reiter RJ, Garcia-Maurino E, Osuna C, Guerrero JM. Physiological levels of melatonin contribute to the antioxidant capacity of human serum. J Pineal Res 1999; 27: 59-64.
23. Miles LE, Dement WC. Sleep and aging. Sleep 1980; 3: 119-220.
24. Pandi-Perumal SR, Seils LK, Kayumov L et al. Senescence, sleep, and circadian rhythms. Aging Res Rev 2002; 1: 559-604.
25. Cajochen C, Kräuchi K, Wirz-Justice A. Role of melatonin in the regulation of human circadian rhythms and sleep. J Neuroendocrinol 2003; 15: 432-437.
26. Skene D, Lockley SW, Arendt J. Use of melatonin in the treatment of phase shift and sleep disorders. Adv Exp Med Biol 1999; 467: 79-84.
27. Zisapel N. The use of melatonin for the treatment of insomnia. Biol Signals Recept 1999; 9: 84-89.
28. Monti, JM; Cardinali, DP. A critical assessment of the melatonin effect on sleep in humans. Biol Signals Recept 2000, 9, 328-339.
29. Cardinali DP, Brusco LI, Lloret SP, Furio AM. Melatonin in sleep disorders and jet-lag. Neuro Endocrinol Lett 2002; 23(suppl 1): 9-13.
30. Baskett JJ, Broad JB, Wood PC et al. Does melatonin improve sleep in older people? A randomized crossover trial. Age Ageing 2003; 32: 164-170.
31. Lavie P, Haimov I, Shochat T. Melatonin - shutting off the wakefulness system. Front Horm Res 1997; 23: 149-160.
32. Paul, MA; Gray, G; Kenny, G; Pigeau, RA. Impact of melatonin, zaleplon, zopoclone, and temazepam on psychomotor performance. Aviat Space Environ Med 2003; 74: 1263-1270.
33. Hofman MA, Swaab DF. Neuroplasticity in the human hypothalamus during ageing, In: The Neuroendocrine Immune Network in Ageing, Vol. 4, RH Straub, E Mocchegiani (eds). Amsterdam: Elsevier; 2004; pp. 105-121.
34. Armstrong SM. Melatonin: the internal Zietgeber of mammals? Pineal Res Rev 1989; 7: 157-202.
35. Armstrong SM, Redman JR. Melatonin: A chronobiotic with anti-aging properties. Med Hypotheses 1991; 4: 300-309.
36. Arendt J, Deacon S. Treatment of circadian rhythm disorders - melatonin. Chronobiol Int 1997; 14: 185-204.
37. Skene DJ, Lockley SW, Arendt, J. Melatonin in circadian sleep disorders in the blind. Biol Signals Recept 1999; 8: 90-95.
38. Walford RL. The Immunologic Theory of Aging. Copenhagen: Munsksgaard; 1989.
39. Fulop T, Hirokawa K, Mocchegiani E et al. The immune system in the elderly. In Aging and Age-Related Diseases: the Basics, M Karasek (ed). Hauppage, NY, Nova Science, 2006, pp. 173-196.
40. Pawelec G, Barnett Y, Forsey R et al.. T cell immunosenescence. Front Biosc 2002; 7: d1056-d1183.
41. Skwarło-Sońta K, Karasek M. Układ odpornościowy, starzenie siȩ a melatonina. Aktualności Neurologiczne, 2003; 3: 215-220..
42. Guerrero JM, Reiter RJ. Melatonin-immune system relationships. Curr Top Med Chem 2002; 2: 167-179.
43. Maestroni GJM The immunotherapeutic potential of melatonin. Expert Opin Investig Drugs 2001; 10: 467-476.
44. Carrillo-Vico A, Guerrero JM, Lardone PJ, Reiter RJ. A review of the multiple actions of melatonin on the immune system. Endocrine 2005; 27: 189-200.
45. Nelson RJ, Drazen DL. Melatonin mediates seasonal changes in immune function. Ann NY Acad Sci 2000; 917: 404-415.
46. Molinero P, Soutto M, Benot S, Hmadcha A, Guerrero JM. Melatonin is responsible for the nocturnal increase observed in serum and thymus of thymosin a1 and thymulin concentrations: observations in the rats and humans. J Neuroimmunol 2000; 103: 180-188.
47. Carrillo-Vico A, Calvo JR, Abreu P et al. Evidence of melatonin synthesis by human lymphocytes and its physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004; 18: 537-539.
48. Carrillo-Vico A, Lardone PJ, Fernandez-Santos J et al. Human lymphocyte-synthesized melatonin is involved in the regulation of the IL-2/IL-2 receptor system. J Clin Endocrinol Metab 2005; 90: 992-1000.
49. Karasek M, Reiter RJ, Cardinali DP, Pawlikowski M. The future of melatonin as a therapeutic agent. Neuro Endocrinol Lett 2002; 23 (suppl 1): 118-121.
50. Reiter RJ, Tan DX, Sainz RM, Mayo JC, Lopez-Burillo S. Melatonin: reducing the toxicity and increasing the efficacy of drugs. J Pharm Pharmacol 2002; 54: 1299-1321.